Choroidal Thickness Change in Central Serous Chorioretinopathy after Photodynamic Therapy Using Optical Coherence Tomography

Mücella Arıkan Yorgun

doi:10.5152/EurJTher.2018.646

Authors

Mücella Arıkan Yorgun Clinic of Ophthalmology, Ankara Atatürk Training and Research Hospital, Ankara https://orcid.org/0000-0003-0069-2433

DOI:

https://doi.org/10.5152/EurJTher.2018.646

Keywords:

Central serous chorioretinopathy, choroidal thickness, optical coherence tomography, photodynamic therapy

Abstract

Objective: This study aimed to evaluate the change in choroidal thickness and subanalyze Haller’s and Sattler’ layer in patients with central serous chorioretinopathy (CSC) following low-fluence photodynamic therapy (PDT) using enhanced depth imaging optical coherence tomography (EDI-OCT).
Methods: In this retrospective study, medical records of the patients with CSC were reviewed. Patients with a diagnosis of CSC and a history of decreased visual acuity for more than six months and treated with half-dose PDT with verteporfin were included in the study. Patients who received previous PDT for chronic CSC or had evidence of choroidal neovascular membrane were excluded. Main outcome measures were the change in choroidal thickness and subanalysis of Haller and Sattler layer after treatment.
Results: A total of 13 eyes of 13 patients were included in the study. The mean age of the patients was 49±11 years (range 40–68). The mean subfoveal choroidal thickness decreased significantly from 310.60±89.16 μm at baseline to 308.41±90.03 μm after PDT (p<0.05). The mean Haller’s layer thickness decreased significantly from 203.40±86.37 μm to 200.20±81.55 μm (p<0.05). The thickness of Sattler’ layers did not differ significantly after PDT treatment (p>0.05).
Conclusion: Half-fluence PDT for CSC resulted in thinner subfoveal choroidal thickness after PDT treatment. Sattler’s layer had similar thickness in eyes with active CSC and after PDT. This study finding suggested that subfoveal choroidal thickness changes after half-dose PDT were likely due to the changes in Haller’s layer.

Metrics

Metrics Loading ...

References

Iacono P, Battaglia Parodi M, Falcomatà B, Bandello F. Central Serous Chorioretinopathy Treatments: A Mini Review. Ophthalmic Res 2015; 55: 76-83.

Gülkaş S, Şahin Ö. Current therapeutic approaches to chronic central serous chorioretinopathy. Turk J Ophthalmol 2019; 49: 30-9.

Gemenetzi M, De Salvo G, Lotery AJ. Central serous chorioretinopathy: an update on pathogenesis and treatment. Eye (Lond) 2010; 24: 1743-56.

Quin G, Liew G, Ho IV, Gillies M, Fraser-Bell S. Diagnosis and interventions for central serous chorioretinopathy: review and update. Clin Exp Ophthalmol 2013; 41: 187-200.

Goldhagen BE, Goldhardt R. Diagnosed a Patient with Central Serous Chorioretinopathy? Now What?: Management of Central Serous Chorioretinopathy. Curr Ophthalmol Rep 2017; 5: 141-8.

Lee JY, Chae JB, Yang SJ, Kim JG, Yoon YH. Intravitreal bevacizumab versus the conventional protocol of photodynamic therapy for treatment of chronic central serous chorioretinopathy. Acta Ophthalmol 2011; 89: e293-4. 7. Ruiz-Moreno JM, Lugo FL, Armada F, Silva R, Montero JA, Arevalo JF, et al. Photodynamic therapy for chronic central serous chorioretinopathy. Acta Ophthalmol 2010; 88: 371-6.

Van Rijssen TJ, Van Dijk EHC, Yzer S, Ohno-Matsui K, Keunen JEE, Schlingemann RO, et al. Central serous chorioretinopathy: Towards an evidence-based treatment guideline. Prog Retin Eye Res 2019; Jul 15. pii: S1350-9462(18)30094-6.

Spaide RF, Koizumi H, Pozzoni MC. Enhanced depth imaging spectral-domain optical coherence tomography. Am J Ophthalmol 2008; 146: 496-500.

Kang NH, Kim YT. Change in subfoveal choroidal thickness in central serous chorioretinopathy following spontaneous resolution and low-fluence photodynamic therapy. Eye (Lond) 2013; 27: 387-91.

Imamura Y, Fujiwara T, Margolis R, Spaide RF. Enhanced depth imaging optical coherence tomography of the choroid in central serous chorioretinopathy. Retina 2009; 29: 1469-73.

Chung YR, Kim JW, Kim SW, Lee K. Choroidal Thickness In Patients With Central Serous Chorioretinopathy: Assessment of Haller and Sattler Layers. Retina 2016; 36: 1652-17.

Chan WM, Lai TY, Lai RY, Tang EW, Liu DT, et al. Safety enhanced photodynamic therapy for chronic central serous chorioretinopathy: one-year results of a prospective study. Retina 2008; 28: 85-93.

Jirarattanasopa P, Ooto S, Tsujikawa A, Yamashiro K, Hangai M, Hirata M, et al. Assessment of macular choroidal thickness by optical coherence tomography and angiographicchanges in central serous chorioretinopathy. Ophthalmology 2012; 119: 1666-78.

Maruko I, Iida T, Sugano Y, Ojima A, Sekiryu T. Subfoveal choroidal thickness in fellow eyes of patients with central serous chorioretinopathy. Retina 2011; 31: 1603-8.

Maruko I, Iida T, Sugano Y, Ojima A, Ogasawara M, Spaide RF. Subfoveal choroidal thickness after treatment of central serous chorioretinopathy. Ophthalmology 2010; 117: 1792-9.

Dansingani KK, Balaratnasingam C, Naysan J, Freund KB. En face imaging of pachychoroid spectrum disorders with swept-source optical coherence tomography. Retina 2016; 36: 499-516.

Yang L, Jonas JB, Wei W. Choroidal vessel diameter in central serous chorioretinopathy. Acta Ophthalmol 2013; 91: e358-62.

Chan WM, Lam DS, Lai TY, Tam BS, Liu DT, Chan CK. Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease level. Br J Ophthalmol 2003; 87: 1453-8.

Povazay B, Hofer B, Torti C, Hermann B, Tumlinson AR, Esmaeelpour M, et al. Impact of enhanced resolution, speed and penetration on three-dimensional retinal optical coherence tomography. Optics Express 2009; 17: 4134-50.